Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies

• Published in: Critical reviews in oncology/hematology Vol. 131; pp. 96 - 101
• Main Authors: He, Ming Yuan, Rancoule, Chloé, Rehailia-Blanchard, Amel, Espenel, Sophie, Trone, Jane-Chloé, Bernichon, Emilie, Guillaume, Elodie, Vallard, Alexis, Magné, Nicolas
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-11-2018
• Subjects: Molecular subtypes; Radiation therapy; Radiosensitization; Triple negative breast cancer; Molecular subtypes; Radiosensitization; Radiation therapy; Triple negative breast cancer
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2018.09.004

Triple-negative breast cancer (TNBC) (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is viewed as an aggressive subgroup of breast cancer. Treating patients with TNBC remains clinically challenging. It’s now well established than radiation therapy is able to improve locoregional control in breast cancer patients both after breast conserving surgery or mastectomy, with positive impact in high-risk patients for long-term survival. Biologic characterization of breast tumor different subtypes, in particular the heterogeneous subtype of TNBC could permit to adapt the treatment plan. In the present review, summarizing the molecular types, we describe clinical features and postoperative radiotherapy current situation for TNBC, and we provide new strategies and directions through an adapted radiation therapy.